CPRX
$4.44
Catalyst Pharm
($.26)
(5.53%)
CPRX
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  $0.13
Revenue:  N/A
Tuesday
Feb 11
4:40 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Guidance announcement made Tuesday, November 12, 2019

What do you expect when CPRX reports earnings?
Beat
Meet
Miss

Where is CPRX's stock price going from here?
Up
Flat
Down
Stock chart of CPRX
Analysts
Summary of analysts' recommendations for CPRX
Score
Grade
Pivots
Resistance
$5.26
$5.04
$4.87

$4.65

Support
$4.48
$4.26
$4.09
Tweet
Growth
Description
CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending worldwide. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted Fast Track status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsCelgeneInterCeptJohnson & JohnsonMylanZoetisEndo International plcUltragenyx Pharmaceutical